With new research and commercial test launches, clincians anticipate exciting new tools but judging quality and utility has become challenging.
Researchers hope to identify exosomal biomarkers that can predict or detect cancer recurrence and metastasis at its earliest stages.
New data from Peregrine Pharmaceuticals, along with other recent research, suggests that surface proteins can be used to isolate cancer-specific exosomes to detect the presence of a tumor.
Researchers showed it could differentiate pancreatic cancer cases from controls with high sensitivity, and believe it could work similarly for other cancers or in infectious disease.
The company developed the instrument using in-licensed technology coupled with its own chemistry and other technology for exosomal protein analysis.
With an initial focus on exosome biology, the technology giant is looking for ways to use the microfluidic chip, which can sort particles as small as 20 nanometers.
The partners have a long-standing sponsored research agreement focused on phosphatidylserine, a signaling molecule found in tumor exosomes.
The partners will develop a biomarker discovery platform based on Exosome Diagnostics' exosomal RNA sequencing technology.
The company plans to make the platform available to collaborators conducting research on exosomal biomarkers with the aim of development new diagnostics.
The method may allow for higher resolution analysis of liquid biopsy samples, and could be useful for monitoring and guiding treatment for cancer patients.
Dog DNA testing finds that some purebreds might not truly be purebreds, Inside Edition reports.
Mary Beckerle has returned as director of the Huntsman Cancer Institute, according to ScienceInsider.
Smithsonian Magazine reports that environmental DNA sampling can be used to track elusive organisms.
In Genome Research this week: repetitive satellite DNA in the fruit fly, transcriptome map assembly pipeline, and more.